Total Revenue: Approximately $555 million for Q1 2025. Cabozantinib Franchise Net Product Revenue: $513.3 million for Q1 2025. CABOMETYX Net Product Revenue: $510.9 million, including $12 million in clinical trial sales. Gross to Net for Cabozantinib Franchise: 28.9% in Q1 2025. Operating Expenses: Approximately $369 million for Q1 2025. GAAP Net Income: Approximately $159.6 million or $0.57 per share basic and $0.55 per share diluted. Non-GAAP Net Income: Approximately $179.6 million or $0.64 per share basic and $0.62 per share diluted. Cash and Marketable Securities: Approximately $1.65 billion as of March 31, 2025. Share Repurchase: Approximately $289 million worth of shares repurchased, retiring approximately 8 million shares at an average price of $35.83 per share. 2025 Full Year Revenue Guidance: Increased to $2.05 billion to $2.15 billion for net product revenue and $2.25 billion to $2.35 billion for total revenue. Warning! GuruFocus has detected 5 Warning Sign with EXEL. Release Date: May 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Exelixis Inc (NASDAQ:EXEL) reported a strong first quarter with significant progress across all business components. The US cabo franchise saw a 36% year-over-year growth in net product revenues, reaching $513 million. Exelixis Inc (NASDAQ:EXEL) received US regulatory approval for CABOMETYX in neuroendocrine tumors ahead of schedule. The company increased its 2025 full-year financial guidance for net product revenues and total revenues by $100 million. Exelixis Inc (NASDAQ:EXEL) is advancing new molecules from its pipeline, with Zanza expected to be a key oncology franchise opportunity in 2025. Negative Points Gross to net deductions increased in the first quarter of 2025 due to higher PHS and 340B volumes. The company experienced little inventory destocking, which could impact future inventory management. Exelixis Inc (NASDAQ:EXEL) faces risks related to product commercial success, market competition, and regulatory review processes. The development program for XL495 was discontinued due to drug-related toxicities. There is uncertainty regarding the early trajectory and stabilization of the neuroendocrine tumor launch. Q & A Highlights Q: Could you help us understand what's been driving cabozantinib growth, and provide some color on the launch in neuroendocrine tumors? A: The growth is primarily driven by renal cell carcinoma (RCC), particularly frontline RCC with the cabo/nivo combination. The CheckMate 9ER 5-year follow-up data has resonated well with physicians. Regarding neuroendocrine tumors (NET), there was some utilization before approval, but the launch is in early days. Feedback from prescribers is positive, and the team is actively promoting the drug. Story Continues Q: Did you see a bolus effect in the early days of the NET launch, and when do you expect it to stabilize? A: We don't expect a bolus effect due to the advanced stage of disease in NET patients. There is significant prescriber excitement, and we are seeing new prescriptions. We will continue to monitor trends as the launch progresses. Q: Can you provide context on the seasonality for cabozantinib this year? A: The seasonality seen in past years is gone due to our specified small manufacturer designation, which stabilizes gross to net across the year. We project gross to net to be in the 29% to 30% range, and there were no significant inventory dynamics this year. Q: Regarding the full year's 2025 guidance increase, how much of it comes from NET? A: The majority of the guidance increase is driven by the RCC-based business, with a smaller contribution from NET. We are tracking the momentum closely and will update guidance when we have more confidence. Q: How does the current environment influence your business development plans? A: We are open for business development, focusing on high-conviction assets within GU and GI oncology. We aim to convert differentiating clinical data into commercial success, similar to the cabo story. We are not looking to buy on the cheap but are focused on high science and moving the needle for patients. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. View Comments
Exelixis Inc (EXEL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...